Distinguished in Melanoma

Muhammad A. Khattak

35 Stirling Highway, 
Crawley, WA, AU 
Distinguished in Melanoma
35 Stirling Highway, 
Crawley, WA, AU 
OverviewLocationsClinical Research

Overview

Muhammad Khattak practices in Crawley, Australia. Mr. Khattak is rated as a Distinguished expert by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Colorectal Cancer, Uveal Melanoma, and Tissue Biopsy.

His clinical research consists of co-authoring 62 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 44 articles in the study of Melanoma.

Gender
Male

Locations

35 Stirling Highway, Crawley, WA 6009, Australia
Other Locations
Woodville Rd, Woodville, SA 5011, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma
A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma
Enrollment Status: Terminated
Publish Date: May 06, 2022
Intervention Type: Drug, Biological
Study Drugs: APL-501, APL-101, Nivolumab
Study Phase: Phase 1/Phase 2

62 Total Publications

Prognostic Value of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Lactate Dehydrogenase Level in Melanoma Patients Treated with Immune Checkpoint Inhibitors.
Prognostic Value of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Lactate Dehydrogenase Level in Melanoma Patients Treated with Immune Checkpoint Inhibitors.
Journal: Cancer investigation
Published: November 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Khattak's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile